At the European Society of Cardiology (ESC) Congress 2025, which will be held in Madrid, Spain from August 29 to September 1, Novo Nordisk stated today that it will showcase compelling new data proving the life-saving cardiovascular benefits of its semaglutide medications, Wegovy®, Ozempic®, and Rybelsus®.
Key Cardiovascular Findings
According to the pharmaceutical giant’s most recent studies, semaglutide lowers the risk of cardiovascular events by 20–26%, which means that individuals with diabetes and obesity are less likely to die, have heart attacks, strokes, or be hospitalized. This notable decrease highlights the promise of semaglutide as a revolutionary medication for cardiovascular protection.
Read More: Novo Nordisk’s Wegovy® (Semaglutide) Receives FDA Approval for MASH Treatment
Major Study Highlights
Wegovy® (Semaglutide 2.4 mg) Breakthrough
The results of the SELECT study will show how Wegovy affects atrial fibrillation, a common heart rhythm disorder that affects obese people. This is a big step in understanding how GLP-1 receptor agonists can address cardiac arrhythmias beyond standard metabolic advantages.
Expanded Benefits Across Patient Populations
New cardiometabolic benefits for Rybelsus® and Ozempic® in individuals with type 2 diabetes will be shown by additional data from the SOUL and STRIDE investigations, indicating improvements in both metabolic and cardiac health.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Focus on Cardiovascular Inflammation
The function of inflammation in atherosclerotic cardiovascular disease (ASCVD) will be covered in considerable detail in the presentations. ASCVD happens when blood arteries narrow and stiffen, preventing blood from reaching essential organs.
- Examination of the correlations between mortality and C-reactive protein levels.
- Evidence from the real world that inflammation affects significant cardiovascular events.
- Implications of healthcare costs for people with chronic renal disease and ASCVD.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
